Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Jumia Technologies AG - ADR — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.69 (market cap $6.04B), while Jumia Technologies AG - ADR trades at $6.24 (market cap $865.90M). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 7× Jumia Technologies AG - ADR's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Jumia Technologies AG - ADR for 28 Days on average.
| IOVA | JMIA | |
|---|---|---|
Market Cap | $6.04B | $865.90M |
Volume | 14,805,993 | 1,695,227 |
Sector | Health | Consumer Cyclical |
52-Week High | $14.82 | $14.60 |
52-Week Low | $1.81 | $5.69 |
Typical Hold Time | 0 Days | 28 Days |
Enterprise Value | $5.97B | $831.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JMIA stock trades at $6.315, down 6.31% today, amid a bearish technical signal. The company reported revenue of $188.93M in 2025 with a net loss of $61.55M, though losses are narrowing year-over-year. Analyst consensus is bullish with a $12.00 price target, and recent news highlights a $50M capital raise and progress toward EBITDA breakeven by year-end 2026.
The outlook hinges on JMIA achieving profitability targets, with upside potential from analyst targets but risks from persistent losses and high valuation multiples. Execution on cost control and African e-commerce growth are critical for stock performance, while cash flow volatility remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
